Medication-induced acute kidney injuryGoldstein, Stuart L.Current Opinion in Critical Care: December 2016 - Volume 22 - Issue 6 - p 542–545 doi: 10.1097/MCC.0000000000000355 RENAL SYSTEM: Edited by John Kellum Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review The present article will review the current state of our understanding of nephrotoxic medication-associated acute kidney injury (AKI) and provide strategies to reduce its impact. Recent findings Nephrotoxic medications contribute to a substantial proportion of AKI in hospitalized patients. The previous perspective of nephrotoxic medication-associated AKI as a nonmodifiable necessary evil of providing appropriate therapy to ill patients had led to an incomplete understanding of its epidemiology and provided little impetus to reduce its occurrence. Summary Recent work on understanding specific combinations, thresholds for nephrotoxic burden and systematic kidney function assessment had mitigated, and even in some cases reduced, nephrotoxic AKI rates and severity. Current initiatives are underway to further refine specific nephrotoxic medication AKI risk via novel urinary biomarkers and genetic susceptibility. Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA Correspondence to Stuart L. Goldstein, MD, Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue MLC 7022, RILF2, Cincinnati, OH 45229. Tel: +1 513 803 3295; fax: +1 513 803 3312; e-mail: email@example.com Copyright © 2016 YEAR Wolters Kluwer Health, Inc. All rights reserved.